+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Renal Biomarkers Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175807
  • Report
  • August 2020
  • Region: Global
  • 119 pages
  • Mordor Intelligence
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Abbott Laboratories
  • BioMérieux
  • BioPorto Diagnostics AS
  • F. Hoffmann-La Roche AG
  • Pacific Biomarkers
  • Randox Laboratories Ltd
  • MORE
The global renal biomarkers market has been witnessing a CAGR of 7.2%. The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics.
  • Advancements in the field of genetic technology during the last decade have enlightened people's knowledge regarding genetic regulatory pathways related to renal biomarkers. Due to rapid advances in genomic technologies, genetics analysis has become essential in clinical practice and research. Moreover, with the development of computer technology, renal biomarkers testing has become widely accessible and feasible to perform, even in small-sized laboratories. Recent advances in genetics have created opportunities to study kidney disease in a variety of platforms, applied to human populations. Renal biomarkers can also be integrated into genetic-level technological advancements for the detection, diagnosis, and treatment of kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drives the market.
Key Market Trends

Functional Biomarker is Expected to Hold a High Market Share in the Biomarker Type Segment

In the biomarker type, the functional biomarker is believed to have the largest market share. Chronic kidney disease (CKD) has become a public health problem. According to the National Institute of Diabetes, Digestives, and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made by the testing of levels of serum creatinine (SCr). The serum creatinine, a functional biomarker, dominates the market for renal biomarkers, owing to the high prevalence rate of CKD and high presence and knowledge of serum creatinine biomarkers.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. In the past decade, there was a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures.

Molecular biomarkers are expected to be identified and validated in drug development and used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.

Competitive Landscape

The renal biomarkers market is highly competitive and consists of several major players, along with multiple smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies at affordable prices. Companies, like Thermofisher Scientific, Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche, and BioMérieux, hold substantial shares in the market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5


  • Abbott Laboratories
  • BioMérieux
  • BioPorto Diagnostics AS
  • F. Hoffmann-La Roche AG
  • Pacific Biomarkers
  • Randox Laboratories Ltd
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Various Kidney-related Diseases
4.2.2 High Prevalence of Diabetes and High Blood Pressure, the Leading Cause of Renal Diseases
4.2.3 Rapid Technological Advances in the Field of Genetics
4.3 Market Restraints
4.3.1 Issues Related to Regulatory and Reimbursement Systems
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Biomarker Type
5.1.1 Functional Biomarker Serum Creatinine Serum Cystatin C Urine Albumin
5.1.2 Up-regulated Protein Neutrophil Gelatinase-Associated Lipocalin (NGAL) Kidney Injury Molecule-1 INTERLEUKIN-18
5.1.3 Other Biomarker Types
5.2 Diagnostic Technique
5.2.1 Enzyme-linked Immunosorbent Assay
5.2.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
5.2.3 Colorimetric Assay
5.2.4 Chemiluminescent Enzyme Immunoassay (CLIA)
5.2.5 Liquid Chromatography Mass Spectrometry (LS-MS)
5.3 End User
5.3.1 Hospital
5.3.2 Diagnostic Laboratory
5.3.3 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 BioPorto Diagnostics AS
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 Pacific Biomarkers
6.1.6 BioMérieux
6.1.7 Beckman Coulter (Danaher Corporation)
6.1.8 Randox Laboratories Ltd
6.1.9 Siemens Healthineers

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Abbott Laboratories
  • BioPorto Diagnostics AS
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Pacific Biomarkers
  • BioMérieux
  • Beckman Coulter (Danaher Corporation)
  • Randox Laboratories Ltd
  • Siemens Healthineers
Note: Product cover images may vary from those shown
5 of 5